- Home
- VNO vs LEGN Comparison
VNO vs LEGN Comparison
Compare VNO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | LEGN |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VNO | LEGN |
|---|---|---|
| Price | $35.14 | $22.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $38.33 | ★ $69.67 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $1,903,939,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $68.83 |
| Revenue Next Year | $2.19 | $51.27 |
| P/E Ratio | $8.42 | ★ N/A |
| Revenue Growth | 1.75 | ★ 74.75 |
| 52 Week Low | $29.68 | $22.28 |
| 52 Week High | $45.53 | $45.30 |
Technical Indicators
Market Signals| Indicator | VNO | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 21.96 |
| Support Level | $34.27 | $26.43 |
| Resistance Level | $35.74 | $28.97 |
| Average True Range (ATR) | 1.10 | 1.57 |
| MACD | 0.09 | -0.43 |
| Stochastic Oscillator | 39.89 | 0.91 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.